Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ShangPharma Announces Third Quarter 2011 Results


      News provided by

      ShangPharma Corporation

      Nov 21, 2011, 05:57 ET

      Share this article

      Share this article


      SHANGHAI, Nov. 21, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended September 30, 2011.

      To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes expenses relating to or the effect of share-based compensation. See "About Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Data" below for more information about the non-GAAP financial measures included in this press release.

      Third Quarter 2011 Highlights

      • Net revenues increased by 24.7% year-over-year to $28.8 million.
      • Net revenues from China-based customers increased by 105.9% year-over-year to $3.1 million.
      • GAAP gross margin was 31.2%, compared with 32.5% in the third quarter of 2010. Non-GAAP gross margin was 33.4% compared with 33.3% in the third quarter of 2010.
      • GAAP operating margin was 7.2%, compared with 13.4% in the third quarter of 2010. Non-GAAP operating margin was 13.4% compared with 14.6% in the third quarter of 2010, primarily due to the additional rental costs associated with our new facility dedicated to one of our top customers.
      • Revenue per employee increased 15.4% year-over-year.
      • Revenue from biologics services grew 184.5% year-over-year.

      Management Comment

      "We experienced robust top-line growth in Q3, as increasing customer appreciation of ShangPharma's integrated service platform and upgrades to our facilities and service quality have enabled us to improve our pricing structure for some projects," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "During the third quarter, we made a critical investment in a new facility, which is fully dedicated to one of our top customers. We expect the near-term margin pressure from this investment to be offset by rapid utilization and additional revenue beginning from 2012."

      Mr. Hui continued, "We saw excellent revenue growth from our biggest multinational pharmaceutical and biotechnology customers, which expanded at a year-on-year rate of 24.3%. Based on our current pipeline of projects, we expect to experience continued strong growth in 2012. We also saw highly encouraging growth from our China-based customers, which more than doubled from the third quarter of 2010. Our success on these two fronts demonstrates strong execution on our strategy to expand cooperation with large multinationals, while diversifying our customer base at the same time."

      William Dai, Chief Financial Officer, added, "In the third quarter, ShangPharma did an excellent job of managing our costs, while also experiencing 15.4% revenue per employee productivity gains. Excluding costs associated with the new facility for one of our largest customers, non-GAAP operating margins remained largely stable year-on-year."

      Third Quarter 2011 Results

      Net revenues were $28.8 million, an increase of 24.7% from $23.1 million in the third quarter of 2010, primarily due to higher volumes from the Company's top customers, an increase in the size of the customer base and greater cross-selling of services.    

      During the quarter, the Company's customer base grew to 362 customers, an increase from 237 customers as of December 31, 2010 and 316 as of June 30, 2011.

      Revenue from customers based in China rose by 105.9%.  The growth came both from local pharmaceutical companies and smaller domestic laboratories, as well as major multinational biotech and pharmaceutical companies' R&D centers in China.

      Revenue from the Company's top-10 customers increased by 24.3% compared with the same period last year, and accounted for 62.2% of the total revenue compared with 62.4% in the same quarter last year. The growth is a result of multinational pharmaceutical companies expanding their scope of work with the Company.

      Net revenues from full-time-equivalent ("FTE")-based services were $20.7 million, an increase of 24.1% from $16.7 million in the third quarter of 2010, due to an increase in FTE services.

      Net revenues from fee-for-service-based services were $8.1 million, an increase of 26.3% from $6.4 million in the third quarter of 2010.  Continued strong demand increases from China-based companies, successful service cross-selling and rapid increased demand for services such as biologics, were the primary drivers of this growth.

      Gross profit was $9.0 million, an increase of 19.9% from $7.5 million in the third quarter of 2010, primarily due to the increase in revenues and operational efficiency improvements.  Continued appreciation of the Renminbi and higher share-based compensation partially offset these increases.

      Non-GAAP gross profit was $9.6 million, an increase of 25.2% from $7.7 million in the third quarter of 2010, primarily due to the increase in revenues and operational efficiency improvements, which was partially offset by the continued appreciation of the Renminbi.

      Gross margin was 31.2%, compared with 32.5% in the third quarter of 2010, primarily due to continued Renminbi appreciation and higher share-based compensation expenses, which were partially offset by operational efficiency improvements.  

      Non-GAAP gross margin was 33.4%, compared with 33.3% in the third quarter of 2010.  The improvement was primarily due to operational efficiency improvements, and was partially offset by continued Renminbi appreciation.

      Operating expenses (selling and marketing, general and administrative) were $6.9 million, an increase of 57.6% from $4.4 million in the third quarter of 2010, primarily due to higher share-based compensation expenses, a build-up of corporate managerial and supporting infrastructure in the second half of 2010, and rental expenses from one additional building leased since July 2011. The new building was still under renovation as of September 30, 2011 and is expected to be put into operation in the end of 2011 for one of our major customers.

      Non-GAAP operating expenses were $5.8 million, an increase of 33.5% from $4.3 million in the third quarter of 2010, primarily due to a build-up of corporate managerial and supporting infrastructure in the second half of 2010 and rental expenses from the additional building leased since July 2011.

      The build-up of corporate managerial and supporting infrastructure was near completion at the end of 2010.  The management team believes that the current infrastructure will be sufficient to support the future growth of the Company in the coming years.

      Profit from operations was $2.1 million, a decrease of 33.5% from $3.1 million in the third quarter of 2010, primarily due to higher share-based compensation expenses, the continued appreciation of the Renminbi and rental expenses from the additional building leased since July 2011. The decline was partially offset by the increase in revenues and operational efficiency improvements.  

      Non-GAAP profit from operations was $3.9 million, an increase of 14.5% from $3.4 million in the third quarter of 2010.  The rise was primarily due to higher gross profit and was partially offset by rental expenses from the additional building leased since July 2011.

      Operating margin was 7.2%, compared with 13.4% in the third quarter of 2010.  The operational efficiency improvements were offset by higher share-based compensation expenses, the continued appreciation of the Renminbi and rental expenses from the additional building leased since July 2011.

      Non-GAAP operating margin was 13.4%, compared with 14.6% in the third quarter of 2010.  The non-GAAP operating margin was impacted by rental expenses from the additional building leased since July 2011. Excluding costs associated with the opening of this building, which reduced non-GAAP operating margin by 1.0% in the third quarter of 2011, non-GAAP operating margin remained relatively stable compared with the third quarter of 2010.

      Net income decreased 27.6% year-over-year to $2.6 million, primarily due to lower profit from operations and lower other income, including a smaller gain recognized on foreign exchange forward contracts. These factors were partially offset by higher interest income.

      Non-GAAP net income was $4.4 million, an increase of 14.1% from $3.9 million in the third quarter of 2010, primarily due to higher non-GAAP profit from operations offset by lower other income.  

      Diluted earnings per ADS were $0.14, which compares with $0.22 in the third quarter of 2010.  

      Non-GAAP diluted earnings per ADS were $0.24, unchanged year-on-year.

      Financial Position  

      As of September 30, 2011, the Company had cash and cash equivalents of $40.6 million and no debt. During the quarter, capital expenditures totaled $8.1 million.  

      Full Year 2011 Guidance

      The Company reconfirms its guidance for full year 2011.  The Company expects:

      • Net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010.  
      • Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010.
      • Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

      This reflects the Company's current view and is subject to change.

      Conference Call

      ShangPharma will host a conference call and live webcast at 8am New York time on November 21, 2011 (9pm Beijing time on November 21, 2011).    

      The dial-in details for the live conference call are as follows:

      - International:                                                                

      +1 718 354 1231



      - United States:

      +1-866-519-4004  

      - United Kingdom:

      +080-8234-6646

      - Hong Kong:

      +852-2475-0994



      Passcode:  SHP




      A live and archived webcast of the conference call will be available on the Investor Relations section of ShangPharma's website at www.shangpharma.com

      A telephone replay of the call will be available for seven days after the conclusion of the conference call from 11am New York time on November 21, 2011 to 11:59pm New York time on November 28, 2011.

      The dial-in details for the replay are as follows:

      - International:                                                                

      +61-2-8235-5000



      - Passcode:

      25392229



      ABOUT SHANGPHARMA CORPORATION

      ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

      Safe Harbor: Forward-Looking Statements

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2011 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

      About Non-GAAP Financial Measures

      To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and non-GAAP Financial Data" set forth at the end of this press release.

      The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

      For further information, please contact:

      ShangPharma Corporation
      Lan Xie
      VP of Finance and Operations
      E-mail: [email protected]

      Brunswick Group
      Josh Gartner
      E-mail: [email protected]
      Phone: 86-10-5960-8600

      SHANGPHARMA CORPORATION
      UNAUDITED CONSOLIDATED BALANCE SHEET
      (in thousands of U.S. dollars, except for ordinary share data)





      December 31,

      September 30,


      2010

      2011




      ASSETS



      Current assets:



       Cash and cash equivalents

      49,160

      40,590

       Restricted cash

      688

      774

       Accounts receivable, net

      16,908

      20,437

       Amounts due from related parties

      -

      111

       Inventories

      1,259

      2,209

       Prepayments and other current assets

      4,779

      4,895

       Deferred tax assets

      315

      -

      Total current assets

      73,109

      69,016

      Non-current assets:



       Derivative assets

      261

      -

       Property, plant, equipment and software, net

      60,147

      78,646

       Land use right, net

      4,221

      6,608

       Other long-term assets

      204

      1,263

      Total non-current assets

      64,833

      86,517

      Total assets

      137,942

      155,533




      LIABILITIES



      Current liabilities:



       Short-term bank borrowings

      755

      -

       Accounts payable

      10,549

      13,865

       Amounts due to related parties

      1,025

      354

       Salary and welfare payable

      4,040

      3,524

       Income tax payable

      1,910

      1,392

       Advance from customers

      1,650

      1,129

       Other payables and accruals

      4,477

      6,039

       Deferred tax liabilities

      -

      210

      Total current liabilities

      24,406

      26,513

      Total liabilities

      24,406

      26,513

      Commitments and contingencies






      EQUITY



      Ordinary shares (US$0.001 par value; 429,999,350 shares authorized;
      335,600,000 and 336,108,932 shares issued and outstanding as of
      December 31, 2010 and September 30, 2011, respectively)

      336

      336

      Additional paid in capital

      78,989

      83,239

      Statutory reserves

      6,795

      6,795

      Retained earnings

      23,655

      32,612

      Accumulated other comprehensive income

      3,761

      6,475

        Less: Treasury stock

      -

      (437)

      Total equity

      113,536

      129,020

      Total liabilities and equity

      137,942

      155,533



      SHANGPHARMA CORPORATION
      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
      (in thousands of U.S. dollars, except for ADS(1) data and per ADS data)









      Three months ended

      Nine months ended


      September 30,

      September 30,


      2010

      2011

      %
      Change

      2010

      2011

      %
      Change








      Net revenue

      23,118

      28,836

      24.7%

      64,673

      81,118

      25.4%

      Cost of revenue

      (15,615)

      (19,843)

      27.1%

      (42,824)

      (54,977)

      28.4%

      Gross profit

      7,503

      8,993

      19.9%

      21,849

      26,141

      19.6%








      Operating expenses







          Selling and marketing

      (516)

      (654)

      26.7%

      (1,590)

      (1,715)

      7.9%

          General and administrative

      (3,880)

      (6,326)

      63.0%

      (10,784)

      (17,107)

      58.6%

          Other operating income2

      -

      157


      -

      157


          Other operating expenses2

      -

      (103)


      -

      (103)


      Total operating expenses

      (4,396)

      (6,926)

      57.6%

      (12,374)

      (18,768)

      51.7%








      Profit from operations

      3,107

      2,067

      -33.5%

      9,475

      7,373

      -22.2%








      Other income, net:

      978

      867

      -11.3%

      2,428

      3,270

      34.7%

      Income from operations before income taxes

      4,085

      2,934

      -28.2%

      11,903

      10,643

      -10.6%








      Income taxes

      (505)

      (341)

      -32.5%

      (1,452)

      (1,687)

      16.2%

      Net income

      3,580

      2,593

      -27.6%

      10,451

      8,956

      -14.3%








      Allocation to preferred shareholders

      (901)

      -

      -100.0%

      (2,631)

      -

      -100.0%

      Net income attributable to ordinary shareholders

      2,679

      2,593

      -3.2%

      7,820

      8,956

      14.5%








      Net income attributable to ordinary shareholders per ADS







          Basic

      0.23

      0.14

      -39.1%

      0.68

      0.48

      -29.4%

          Diluted

      0.22

      0.14

      -36.4%

      0.66

      0.48

      -27.3%








      Weighted average ADS outstanding







          Basic

      11,555,888

      18,663,303


      11,555,888

      18,653,889


          Diluted

      11,955,735

      18,715,098


      11,846,880

      18,827,730




      SHANGPHARMA CORPORATION
      RECONCILIATION OF UNAUDITED GAAP TO NON-GAAP FINANACIAL DATA
      (in thousands of U.S. dollars, except for ADS (3) data and per ADS data)


      Three months ended

      Nine months ended


      September 30,

      September 30,


      2010

      2011

      %

      2010

      2011

      %

      GAAP gross profit

      7,503

      8,993

      19.9%

      21,849

      26,141

      19.6%

      GAAP gross margin

      32.5%

      31.2%


      33.8%

      32.2%


      Adjustments:







         Share-based compensation

      195

      643

      229.7%

      446

      1,631

      265.7%

      Non-GAAP gross profit

      7,698

      9,636

      25.2%

      22,295

      27,772

      24.6%

      Non-GAAP gross margin

      33.3%

      33.4%


      34.5%

      34.2%









      GAAP operating expenses

      (4,396)

      (6,926)

      57.6%

      (12,374)

      (18,768)

      51.7%

      Adjustments:







         Share-based compensation

      80

      1,164

      1355.0%

      182

      2,894

      1490.1%

      Non-GAAP operating expenses

      (4,316)

      (5,762)

      33.5%

      (12,192)

      (15,874)

      30.2%








      GAAP profit from operations

      3,107

      2,067

      -33.5%

      9,475

      7,373

      -22.2%

      GAAP operating margin

      13.4%

      7.2%


      14.7%

      9.1%


      Adjustments:







         Share-based compensation

      275

      1,807

      557.1%

      628

      4,525

      620.5%

      Non-GAAP profit from operations

      3,382

      3,874

      14.5%

      10,103

      11,898

      17.8%

      Non-GAAP operating margin

      14.6%

      13.4%


      15.6%

      14.7%









      GAAP net income

      3,580

      2,593

      -27.6%

      10,451

      8,956

      -14.3%

      GAAP net margin

      15.5%

      9.0%


      16.2%

      11.0%


      Adjustments:







         Share-based compensation

      275

      1,807

      557.1%

      628

      4,525

      620.5%

      Non-GAAP net income

      3,855

      4,400

      14.1%

      11,079

      13,481

      21.7%

      Non-GAAP net margin

      16.7%

      15.3%


      17.1%

      16.6%









      GAAP net income attributable to ordinary shareholders per ADS, diluted :

      0.22

      0.14

      -36.4%

      0.66

      0.48

      -27.3%

      Adjustments:







         Share-based compensation

      0.02

      0.10


      0.04

      0.23


      Non-GAAP net income attributable to ordinary shareholders per ADS, diluted:

      0.24

      0.24

      0.0%

      0.70

      0.71

      1.4%








      Weighted average ADS outstanding - basic (Non-GAAP)

      11,555,888

      18,663,303


      11,555,888

      18,653,889


      Weighted average ADS outstanding - diluted (Non-GAAP)

      11,955,735

      18,715,098


      11,846,880

      18,827,730




      (1) Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.

      (2) Certain government subsidies net of the related costs were reclassified to other operating profits in the third quarter of 2011 to better reflect the nature of such transactions.

      (3) Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.



      SOURCE ShangPharma Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.